Alzinova reports that the vaccine candidate ALZ-101 generates stable IgG antibody levels in plasma and detectable levels in cerebrospinal fluid (CSF) in Alzheimer's patients, according to new data. CSF levels reach at least 0,3 percent of plasma levels, comparable to monoclonal antibodies. Results confirm ALZ-101:'s potential to attack neurotoxic amyloid-beta oligomers in the brain, a key mechanism in Alzheimer's.
ALZ-101 shows stable antibody levels in the brain
Notes
Mentice consolidates operations to Denver
Bio-Works secures million-dollar order from global pharmaceutical company
OncoZenge receives investment proceeds from Yangtian Bio-Pharmaceutical
Xspray Pharma confirms bioequivalence for XS003
Evaxion converts debt of EUR 3,5 million
NEWSLETTER
NEWS
AI-designed proteins are created in seconds
The price of Leqembi needs to be lowered in Japan
Merck gears up in lung diseases with giant acquisition
Upcoming events!
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The market is taking Trump's tariff threat in stride
The EU's new life science strategy – a step in the right direction or just fluff?
